Quebecol Shows Potential to Alleviate Periodontal Tissue Damage and Promote Bone Formation in In Vitro Models

  • ACS Omega. 2021 Oct 13;6(42):27791-27797. doi: 10.1021/acsomega.1c03312.
Sébastien Cardinal  1 ,  Amel Ben Lagha  2 ,  Jabrane Azelmat  2 ,  Daniel Grenier  2
Affiliations
  • 1. Département de biologie, chimie et géographie, Université du Québec à Rimouski, 300 allée des Ursulines, Rimouski, QC, Canada G5L 3A1.
  • 2. Groupe de recherche en écologie buccale, Faculté de médecine dentaire, Université Laval, 2420 rue de la Terrasse, Québec, QC, Canada G1V 0A6.
PMID: 34722979 DOI: 10.1021/acsomega.1c03312
Abstract

Quebecol is a polyphenolic compound initially isolated from Canadian maple syrup in 2011. Recently, our group demonstrated in a macrophage model that quebecol inhibits the secretion of pro-inflammatory cytokines and reduces the activation of the NF-κB transcription factor. In this study, we further explored the therapeutic potential of quebecol against periodontal disease, an inflammatory disorder of Bacterial origin affecting tooth-supporting tissues. More specifically, the effects of this natural compound on matrix metalloproteinase (MMP) activity and macrophage secretion, as well as on the mineralization activity of osteoblasts (bone-forming cells), were investigated. Results showed that exposing lipopolysaccharide (LPS)-treated macrophages to quebecol led to a significant decrease in the secretion of MMP-8 and MMP-9. In addition, quebecol dose dependently inhibited the catalytic activity of MMP-9. Quebecol also enhanced the mineralization activity of osteoblasts. This study brought forward additional evidence to support the potential of quebecol as a nutraceutical agent against periodontitis.

Products